BioCentury | Nov 17, 2017
Clinical News

Spectrum begins Phase II of poziotinib to treat NSCLC

...to develop and commercialize the oral quinazoline-based pan-HER inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). Luye Life Sciences Group Ltd....
...commercialize the product in China (see BioCentury, Sept. 1, 2014 & March 23, 2015 ). Luye Life Sciences Group Ltd....
...DCR), duration of response and safety Status: Phase II started Milestone: NA Allison Johnson HM781-36B NOV12010 poziotinib Hanmi Pharmaceutical Co. Ltd. Luye Life Sciences Group Ltd. Spectrum...
BioCentury | Oct 20, 2017
Clinical News

Spectrum reports Phase II data for poziotinib in NSCLC

...to develop and commercialize the oral quinazoline-based pan-HER inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). Luye Life Sciences Group Ltd....
...commercialize the product in China (see BioCentury, Sept. 1, 2014 & March 23, 2015 ). Luye Life Sciences Group Ltd....
...duration of response and safety Status: Interim Phase II data Milestone: NA Chris Lieu HM781-36B NOV12010 poziotinib Hanmi Pharmaceutical Co. Ltd. Luye Life Sciences Group Ltd. Spectrum...
Items per page:
1 - 2 of 2
BioCentury | Nov 17, 2017
Clinical News

Spectrum begins Phase II of poziotinib to treat NSCLC

...to develop and commercialize the oral quinazoline-based pan-HER inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). Luye Life Sciences Group Ltd....
...commercialize the product in China (see BioCentury, Sept. 1, 2014 & March 23, 2015 ). Luye Life Sciences Group Ltd....
...DCR), duration of response and safety Status: Phase II started Milestone: NA Allison Johnson HM781-36B NOV12010 poziotinib Hanmi Pharmaceutical Co. Ltd. Luye Life Sciences Group Ltd. Spectrum...
BioCentury | Oct 20, 2017
Clinical News

Spectrum reports Phase II data for poziotinib in NSCLC

...to develop and commercialize the oral quinazoline-based pan-HER inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). Luye Life Sciences Group Ltd....
...commercialize the product in China (see BioCentury, Sept. 1, 2014 & March 23, 2015 ). Luye Life Sciences Group Ltd....
...duration of response and safety Status: Interim Phase II data Milestone: NA Chris Lieu HM781-36B NOV12010 poziotinib Hanmi Pharmaceutical Co. Ltd. Luye Life Sciences Group Ltd. Spectrum...
Items per page:
1 - 2 of 2